Clinical and clinical pharmacologic studies of mitoxantrone.
The drug mitoxantrone was given to 31 patients in a phase I clinical trial. The schedule of administration was once weekly for 3 weeks followed by 3 weeks of observation before further treatment. Dose range was from 1.5 to 6 mg/m2. Leukopenia was the dose-limiting toxic effect and thrombocytopenia was mild. Partial alopecia occurred in four of 12 patients evaluable for hair loss. Pharmacokinetic studies employing a fluorometric assay based on DNA binding measured by displacement of ethidium bromide revealed a first-phase half-life of about 15 minutes, with a prolonged subsequent phase. A dose of 6 mg/m2/week x 3 was well-tolerated in patients not heavily pretreated with myelosuppression therapy. Only minor clinical activity was seen with mitoxantrone.
D000328:Adult; D000368:Aged; D000880:Anthraquinones / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone; D009369:Neoplasms / Q000188:drug therapy*; D010976:Platelet Count
D000880:Anthraquinones; D000970:Antineoplastic Agents; D008942:Mitoxantrone